Explore our blogs on various markets

Cell and gene therapies are changing modern medicine, offering new hope for patients with cancer, genetic disorders, and rare diseases. However, the success of these treatments depends on reliable and scalable manufacturing. Current processes are often complex, slow, and dependent on manual steps that introduce risks....

Daré Bioscience is set to launch DARE to PLAY™ Sildenafil Cream, the first evidence-backed topical treatment for female sexual arousal, in late 2025. Partnering with Rosy Wellness, the company has begun an awareness campaign to reduce stigma and provide women with trusted education and support around sexual health.. A Major Step Forward in Women’s Health...

Cancer drugs remain among the most expensive medicines in healthcare. While innovative treatments bring hope, their high cost often restricts access for patients and strains health budgets. . Generic oncology drugs, both small-molecule generics and biosimilar,s have emerged as the most powerful tool to improve affordability. ...

Zug, Switzerland (June 26, 2025) – Galderma has announced two new Phase II clinical trials to study nemolizumab, a drug designed to block the IL-31 receptor. . These trials will focus on patients with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO), two conditions with high unmet medical needs and no approved treatments available.. What is Nemolizumab?...

Roche announced significant progress in its Alzheimer’s disease research portfolio during the Alzheimer’s Association International Conference (AAIC) 2025 in Toronto.. The company presented detailed results from its investigational therapy trontinemab and showcased its Elecsys pTau217 blood test, both of which aim to transform the detection and treatment of Alzheimer’s disease.. Advancing trontinemab with Brainshuttle technology...

Cipla Limited has taken significant strides in its respiratory segment with the planned FY26 launch of its generic version of GlaxoSmithKline’s blockbuster asthma and COPD drug, Advair Diskus®, in the United States. . The move follows the successful completion of Phase-3 clinical trials and the filing of an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (USFDA).. The Advair Opportunity: A Multi-Billion Dollar Market...

The global vaccine market is changing faster than ever, but many businesses, researchers, and policymakers struggle to keep up with the latest shifts.. Ignoring these changes can mean missed opportunities in investment, technology adoption, and public health preparedness. Falling behind could also leave gaps in vaccine access, innovation, and disease prevention....

Patient segmentation in cardiology helps hospitals and clinics group patients based on health risks, behavior, and outcomes.. This allows care teams to provide better, faster, and more personalized treatment.. With the rise of chronic heart diseases and growing data from EHRs and diagnostic tools, segmentation is now more important than ever....

WAYNE, Pa. (June 2, 2025) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing treatments for immuno-inflammatory diseases, has announced the initiation of a Phase 2 clinical trial of its leading drug candidate, bosakitug (ATI-045)....

Lund, Sweden - April 25, 2025: Camurus has announced a major regulatory milestone as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for Oczyesa (CAM2029). This once-monthly treatment is designed for adult patients living with acromegaly, a rare hormonal disorder.. The recommendation is based on strong results from seven clinical trials, including two pivotal Phase 3 studies...